Shares of Moderna Inc. climbed nearly 1% on Friday, reaching levels last seen on Jan. 10, as retail sentiment turned ...

As more cases of bird flu emerge across the country, public health leaders in New York City are watching warily -- and making ...

Moderna won an agreement for its Covid vaccines in Europe on Friday, but Moderna stock reversed its early gains.

Less than a day into his second term, President Donald Trump ordered a freeze on communications at major public health agencies, among other moves that have sent waves through the biopharma industry.

Moderna conducts phase 3 trial for norovirus vaccine as cases rise in the U.S., with results expected in late 2025 or early 2026.

Under the agreement, 17 participating countries could order an updated version of the biotech company's mRNA Covid-19 vaccine for up to four years. The vaccine, marketed as Spikevax in Europe, was ...

Moderna (MRNA) stock gained in the premarket after the company received a tender to supply its COVID-19 vaccine in the EU, ...

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats ...

Moderna shares closed up Thursday gaining momentum following recent comments by Oracle Chairman Larry Ellison about the role of artificial intelligence in revolutionizing cancer treatment.

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

Moderna Inc (MRNA) stock saw a modest uptick, ending the day at $38.5 which represents a slight increase of $2.61 or 7.27% from the prior close of $35.89. The stock opened at $36.35 and touched a low ...

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...